- Home
- Therapeutics
- Internal Medicine & Immunology
- Gastrointestinal
Gastrointestinal
ÃÛÌÒ´«Ã½ has experience in managing clinical studies in all major gastrointestinal indications
ÃÛÌÒ´«Ã½ has extensive experience in conducting gastrointestinal studies
We work across the entire drug development spectrum. Our experience ranges from the initial studies in Phase I through post-marketing efforts in Phase IV.
ÃÛÌÒ´«Ã½ Gastrointestinal experience in last five years:
-
100+
Studies -
26,000+
Patients involved -
9,000+
Sites
Broad disease experience
ÃÛÌÒ´«Ã½'s Gastrointestinal team comprises dedicated drug development experts with significant experience conducting clinical trials for experimental therapeutics in the following diseases:
Diseases |
||
Acid Reflux | Chronic Functional Constipation | Indigestion |
Acute Gastric Pain | Crohn¡¯s Disease | Idiopathic Gastroparesis |
Acute Pancreatitis | Diarrhea | Inflammatory Bowel Disease |
Bowel Prep | Diverticulitis | Irritable Bowel Syndrome |
Celiac | Dyspepsia | Irritable Bowel Syndrome with Constipation |
Chronic Constipation | Eosinophilic Esophagitis | Irritable Bowel Syndrome with Diarrhea |
Colorectal Conditions | Esophagitis | Short Bowel Syndrome |
Constipation | Gastroesophageal Reflux | Traveler's Diarrhea |
Chronic Idiopathic Constipation | GERD | Ulcerative Colitis |
In this section
In this section
- Biosimilars
-
Cardiovascular
- Cell and Gene Therapies
- Central Nervous System
-
Endocrine & Metabolic Disorders
- Hepatology
- Infectious Diseases
- Internal Medicine & Immunology
-
Medical Device
-
Obesity
- Oncology
-
Pediatrics
- Rare & Orphan Diseases
- Vaccines
-
Women's Health
-
Therapeutics insights
- Cardiovascular
- Cell and Gene Therapies
- Central Nervous System
-
Glycomics
- Infectious Diseases
- Hepatology
-
Women's Health Insights
-
Oncology
- Pediatrics
-
Rare and orphan diseases
-
Pushing boundaries in idiopathic pulmonary fibrosis clinical research
-
Advanced therapies for rare diseases
-
Cross-border enrollment of rare disease patients
-
Crossing the finish line: Why effective participation support strategy is critical to trial efficiency and success in rare diseases
-
Diversity, equity and inclusion in rare disease clinical trials
-
Identify and mitigate risks to rare disease clinical programmes
-
Leveraging historical data for use in rare disease trials
-
Natural history studies to improve drug development in rare diseases
-
Patient Centricity in Orphan Drug Development
-
The key to remarkable rare disease registries
-
Pushing boundaries in idiopathic pulmonary fibrosis clinical research